ArticleCancer letters2019

Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.

Jing Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.